Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls.
Information on circulating miRNAs in frontotemporal lobar degeneration is very limited and conflicting results have complicated an interpretation in Alzheimer's disease thus far. In the present study we I) collected samples from multiple clinical centers across Germany, II) defined 3 homogenous...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5945001?pdf=render |
id |
doaj-0504149b9dd245f5988768ee58eb8fe9 |
---|---|
record_format |
Article |
spelling |
doaj-0504149b9dd245f5988768ee58eb8fe92020-11-24T21:54:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019732910.1371/journal.pone.0197329Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls.Johannes DenkFelix OberhauserJohannes KornhuberJens WiltfangKlaus FassbenderMatthias L SchroeterAlexander E VolkJanine Diehl-SchmidJohannes PrudloAdrian DanekBernhard LandwehrmeyerMartin LauerMarkus OttoHolger JahnFTLDc study groupInformation on circulating miRNAs in frontotemporal lobar degeneration is very limited and conflicting results have complicated an interpretation in Alzheimer's disease thus far. In the present study we I) collected samples from multiple clinical centers across Germany, II) defined 3 homogenous patient groups with high sample sizes (bvFTD n = 48, AD n = 48 and cognitively healthy controls n = 44), III) compared expression levels in both CSF and serum samples and IV) detected a limited set of miRNAs by using a MIQE compliant protocol based on SYBR-green miRCURY assays that have proven reliable to generate reproducible results. We included several quality controls that identified and reduced technical variation to increase the reliability of our data. We showed that the expression levels of circulating miRNAs measured in CSF did not correlate with levels in serum. Using cluster analysis we found expression pattern in serum that, in part, reflects the genomic organization and affiliation to a specific miRNA family and that were specifically altered in bvFTD, AD, and control groups. Applying factor analysis we identified a 3-factor model characterized by a miRNA signature that explained 80% of the variance classifying healthy controls with 97%, bvFTD with 77% and AD with 72% accuracy. MANOVA confirmed signals like miR-320a and miR-26b-5p at BH corrected significance that contributed most to discriminate bvFTD cases with 96% sensitivity and 90% specificity and AD cases with 89% sensitivity and specificity compared to healthy controls, respectively. Correlation analysis revealed that miRNAs from the 3-factor model also correlated with levels of protein biomarker amyloid-beta1-42 and phosphorylated neurofilament heavy chain, indicating their potential role in the monitoring of progressive neuronal degeneration. Our data show that miRNAs can be reproducibly measured in serum and CSF without pre-amplification and that serum includes higher expressed signals that demonstrate an overall better ability to classify bvFTD, AD and healthy controls compared to signals detected in CSF.http://europepmc.org/articles/PMC5945001?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Johannes Denk Felix Oberhauser Johannes Kornhuber Jens Wiltfang Klaus Fassbender Matthias L Schroeter Alexander E Volk Janine Diehl-Schmid Johannes Prudlo Adrian Danek Bernhard Landwehrmeyer Martin Lauer Markus Otto Holger Jahn FTLDc study group |
spellingShingle |
Johannes Denk Felix Oberhauser Johannes Kornhuber Jens Wiltfang Klaus Fassbender Matthias L Schroeter Alexander E Volk Janine Diehl-Schmid Johannes Prudlo Adrian Danek Bernhard Landwehrmeyer Martin Lauer Markus Otto Holger Jahn FTLDc study group Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE |
author_facet |
Johannes Denk Felix Oberhauser Johannes Kornhuber Jens Wiltfang Klaus Fassbender Matthias L Schroeter Alexander E Volk Janine Diehl-Schmid Johannes Prudlo Adrian Danek Bernhard Landwehrmeyer Martin Lauer Markus Otto Holger Jahn FTLDc study group |
author_sort |
Johannes Denk |
title |
Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. |
title_short |
Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. |
title_full |
Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. |
title_fullStr |
Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. |
title_full_unstemmed |
Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. |
title_sort |
specific serum and csf microrna profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with alzheimer patients and cognitively healthy controls. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
Information on circulating miRNAs in frontotemporal lobar degeneration is very limited and conflicting results have complicated an interpretation in Alzheimer's disease thus far. In the present study we I) collected samples from multiple clinical centers across Germany, II) defined 3 homogenous patient groups with high sample sizes (bvFTD n = 48, AD n = 48 and cognitively healthy controls n = 44), III) compared expression levels in both CSF and serum samples and IV) detected a limited set of miRNAs by using a MIQE compliant protocol based on SYBR-green miRCURY assays that have proven reliable to generate reproducible results. We included several quality controls that identified and reduced technical variation to increase the reliability of our data. We showed that the expression levels of circulating miRNAs measured in CSF did not correlate with levels in serum. Using cluster analysis we found expression pattern in serum that, in part, reflects the genomic organization and affiliation to a specific miRNA family and that were specifically altered in bvFTD, AD, and control groups. Applying factor analysis we identified a 3-factor model characterized by a miRNA signature that explained 80% of the variance classifying healthy controls with 97%, bvFTD with 77% and AD with 72% accuracy. MANOVA confirmed signals like miR-320a and miR-26b-5p at BH corrected significance that contributed most to discriminate bvFTD cases with 96% sensitivity and 90% specificity and AD cases with 89% sensitivity and specificity compared to healthy controls, respectively. Correlation analysis revealed that miRNAs from the 3-factor model also correlated with levels of protein biomarker amyloid-beta1-42 and phosphorylated neurofilament heavy chain, indicating their potential role in the monitoring of progressive neuronal degeneration. Our data show that miRNAs can be reproducibly measured in serum and CSF without pre-amplification and that serum includes higher expressed signals that demonstrate an overall better ability to classify bvFTD, AD and healthy controls compared to signals detected in CSF. |
url |
http://europepmc.org/articles/PMC5945001?pdf=render |
work_keys_str_mv |
AT johannesdenk specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT felixoberhauser specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT johanneskornhuber specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT jenswiltfang specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT klausfassbender specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT matthiaslschroeter specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT alexanderevolk specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT janinediehlschmid specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT johannesprudlo specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT adriandanek specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT bernhardlandwehrmeyer specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT martinlauer specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT markusotto specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT holgerjahn specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols AT ftldcstudygroup specificserumandcsfmicrornaprofilesdistinguishsporadicbehaviouralvariantoffrontotemporaldementiacomparedwithalzheimerpatientsandcognitivelyhealthycontrols |
_version_ |
1725864666103545856 |